Cargando…

Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis

Background: O(6)-methylguanine-DNA methyltransferase (MGMT) is a specific DNA damage reversal repair protein. The influence of MGMT status on alkylating agent sensitivity in patients with neuroendocrine neoplasms (NENs) is controversial. We conducted a meta-analysis to assess the influence of MGMT s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qi, Zhirong, Tan, Huangying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2020
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098124/ https://www.ncbi.nlm.nih.gov/pubmed/32141507 http://dx.doi.org/10.1042/BSR20194127

Ejemplares similares

Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms
por: Della Monica, Rosa, et al.
Publicado: (2022)

O(6)-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
por: Walter, T, et al.
Publicado: (2015)

O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma
por: Bobola, Michael S., et al.
Publicado: (2014)

Alkylation induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins
por: Bugni, James M., et al.
Publicado: (2008)

Clinicopathological features and outcome for neuroendocrine neoplasms of gastroesophageal junction: A population‐based study
por: Zhang, Panpan, et al.
Publicado: (2018)

The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents
por: Siller, Sebastian, et al.
Publicado: (2021)

Alkylation and Carbamylation Effects of Lomustine and Its Major Metabolites and MGMT Expression in Canine Cells
por: Chakkath, Thushara, et al.
Publicado: (2015)

Nutritional and vitamin status in patients with neuroendocrine neoplasms
por: Clement, Dominique SVM, et al.
Publicado: (2019)

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms
por: Fani, Melpomeni, et al.
Publicado: (2017)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents
por: Ricci, Riccardo, et al.
Publicado: (2019)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors
por: Brighi, Nicole, et al.
Publicado: (2023)

Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis
por: Tsolakis, Apostolos V, et al.
Publicado: (2019)

Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
por: Li, Yongzheng, et al.
Publicado: (2022)

Homogeneous MGMT Immunoreactivity Correlates with an Unmethylated MGMT Promoter Status in Brain Metastases of Various Solid Tumors
por: Ingold, Barbara, et al.
Publicado: (2009)

Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms
por: Stankiewicz, Rafał, et al.
Publicado: (2022)

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
por: Shah, Nameeta, et al.
Publicado: (2011)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021)

A meta-analysis of Prognostic factor of Pancreatic neuroendocrine neoplasms
por: Gao, Yong, et al.
Publicado: (2018)

Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm
por: Shi, Huiying, et al.
Publicado: (2020)

Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
por: Pandith, Arshad A., et al.
Publicado: (2018)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Histopathology of gastrointestinal neuroendocrine neoplasms
por: Hirabayashi, Kenichi, et al.
Publicado: (2013)

Imaging of Pancreatic Neuroendocrine Neoplasms
por: Chiti, Giuditta, et al.
Publicado: (2021)

Neuroendocrine Neoplasms of the Gynecologic Tract
por: Virarkar, Mayur, et al.
Publicado: (2022)

Neuroendocrine neoplasm DFP report
Publicado: (2021)

Neuroendocrine neoplasms of the esophagus and stomach
por: Mastracci, Luca, et al.
Publicado: (2021)

Neuroendocrine neoplasm: Current understanding
por: Lila, AR, et al.
Publicado: (2023)

Advances in medical treatment for pancreatic neuroendocrine neoplasms
por: Li, Yuan-Liang, et al.
Publicado: (2022)

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution Study
por: Shen, Dong, et al.
Publicado: (2014)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

Relationships between MGMT promoter methylation and gastric cancer: a meta-analysis
por: Yu, Dan, et al.
Publicado: (2016)

A Prospective and Retrospective Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Tumors
por: Chen, Yingying, et al.
Publicado: (2020)

Association between MGMT Promoter Methylation and Risk of Breast and Gynecologic Cancers: A Systematic Review and Meta-Analysis
por: Chen, Ru, et al.
Publicado: (2017)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Enzyme activated alkylating agents.
por: Ball, C. R., et al.
Publicado: (1973)

Case Report: Response With Immunotherapy in a Patient With Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gallbladder
por: Liu, Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s1apq23iobuj14mj5ml2urpuk6